TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity.
Saved in:
| Title: | TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity. |
|---|---|
| Authors: | Cheng SS; T-E Meds, Inc., Taipei., Jiang JG; Department of Medicine, Division of Hematology and Oncology, Far Eastern Memorial Hospital, New Taipei City., Lin SC; Department of Medicine, Division of Hematology and Oncology, Far Eastern Memorial Hospital, New Taipei City., Yu YH; Immunwork, Inc., Taipei., Chang TW; T-E Meds, Inc., Taipei, Taiwan; Immunwork, Inc., Taipei., Lim C; T-E Meds, Inc., Taipei, Taiwan; Immunwork, Inc., Taipei. carmaylim0830@gmail.com., Yu YB; Department of Medicine, Division of Hematology and Oncology, Far Eastern Memorial Hospital, New Taipei City, Taiwan; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Graduate Institute of Medicine, Yuan Ze University, Taoyuan. fishie.yu@gmail.com., Chu HM; T-E Meds, Inc., Taipei. |
| Source: | Haematologica [Haematologica] 2026 Apr 01; Vol. 111 (4), pp. 1474-1477. Date of Electronic Publication: 2025 Nov 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
